In Vivo
Pharmacology
Integrated In Vivo Pharmacology Platform | From Concept to Clinic
Aragen’s In Vivo Pharmacology Platform delivers end-to-end preclinical efficacy testing across eight therapeutic specializations, unified under integrated leadership and quality standards. With 2150+ completed studies, 30+ years of experience, and 3 AAALAC-accredited facilities spanning the US and India, we transform drug candidates from target validation through regulatory-ready IND packages.
Unlike fragmented CROs, our platform seamlessly integrates DMPK, in vitro biology, chemical synthesis, and in vivo pharmacology—eliminating logistics delays, accelerating DMTA cycles, and ensuring consistent quality across every development phase. We function as a true scientific partner, not just a service provider.
Platform Overview: [8 Therapeutic Areas + Supporting Services]
Our in vivo platform comprises eight specialized therapeutic areas, each staffed with deep disease expertise, advanced infrastructure, and proven regulatory success. Each therapeutic area features validated disease models, comprehensive biomarker strategies, and seamless integration with complementary in vitro and DMPK capabilities.
Why Choose Aragen’s Integrated Platform
Unified Scientific Leadership
- Single point of accountability across all disciplines
- Consistent protocols and quality standards globally
- Disease-focused therapeutic teams with critical mass of expertise
- Leadership continuity from study design through reporting
Zero Logistics Lag Architecture
- Chemistry, biology, pharmacology and DMPK under one roof
- No inter-vendor shipping delays
- Closed-loop DMTA cycles enable rapid iteration
- Real-time collaboration accelerates candidate advancement
Dual Geography with Unified Standards
- Morgan Hill, USA: Real-time collaboration and US proximity
- Hyderabad & Bangalore: ~40% cost efficiency advantage
- Identical protocols, leadership and quality systems
- Flexible resource scaling based on project needs
InCoRe Digital Platform
- Real-time DMTA tracking
- Integrated project data visibility
- Seamless team collaboration
- 24/7 program progress monitoring
Advanced Analytical Integration
- Imaging: BLI, FLI, X-ray, TD-NMR, Micro-CT and ultrasound
- Biomarker profiling: MSD, ELISA, HTRF, qPCR and flow cytometry
- Digital pathology with AI-powered quantification
- Histopathology, IHC, IF and PK/PD-IVIVC integration
Broad Modality Expertise
- Small and large molecules
- PROTACs, molecular glues, mAbs, bispecific antibodies and ADCs
- RNA therapeutics, ASOs and mRNA-LNP
- Gene therapy platforms
Proven Regulatory Readiness
- OECD GLP-compliant operations
- DABT-certified toxicologists
- FDA, EMA and CDSCO regulatory alignment
- Submission support with 9-month average IND turnaround
Cost-Effective Global Delivery
- Premium science at competitive cost
- Geographic flexibility across US and India
- Consistent quality standards across all sites
- Scalable resources for every stage of development
Therapeutic Areas & Disease Models
Explore our specialized in vivo pharmacology capabilities across eight distinct therapeutic platforms, each with validated models, advanced endpoints, and proven scientific rigor.
Oncology
Integrated Oncology Discovery Solutions. 1050+ validated tumor models including CDX, syngeneic, PDX and humanized models. Target validation through IND enablement, PK/PD and efficacy studies, IVIS live imaging, advanced BLI/FLI imaging, DMTA integration, and clinical translation expertise.
Metabolic Disease
In Vivo Pharmacology for Metabolic Disease. Obesity, Type 1 and Type 2 diabetes, MASH, dyslipidemia, metabolic syndrome and renal fibrosis. 20+7 validated disease models with comprehensive biomarkers, flexible study designs and dual geography delivery.
Fibrosis
In Vivo Fibrosis Models for Drug Development. Liver, pulmonary, renal and cardiac fibrosis models with advanced histopathology, mechanistic biomarkers, anti-fibrotic efficacy evaluation and supporting in vitro and ex vivo assays.
Immuno-Oncology & In Vitro Pharmacology
Immuno-Oncology & In Vitro Pharmacology.
9 validated syngeneic models for checkpoint inhibitor efficacy with immune cell profiling, cell-based assays, target engagement, recombinant systems and biomarker discovery.
Cardiovascular Diseases
Animal Models for Cardiovascular & Haematological Disorders.
Heart failure, pulmonary hypertension, cardiac fibrosis, coagulopathy, haemorrhagic shock and thrombocytopenia supported by 6+ validated disease models, comprehensive biomarker analysis and expertise in complex surgically induced disease models.
Renal Diseases
In Vivo Renal Disease Models.
CKD, DKD, acute kidney disease, obstructive nephritis and membranous nephropathy with 10+ validated models, complex CKD surgical expertise, pharmacology, biomarker and histology analysis.
Infectious Diseases
In Vivo Infectious Disease Models.
Bacterial, viral, fungal and parasitic infection models with efficacy testing, PK/PD assessment, biomarker validation, BSL-2/BSL-3 containment and antibiotic/antiviral development support.
Respiratory Diseases
In Vivo Respiratory Disease Models.
Asthma, COPD, pulmonary fibrosis and acute respiratory disease models featuring inhalational delivery, lung function assessment, airway hyperresponsiveness and translational biomarkers.
Pain
In Vivo Pain Models for Drug Development. Acute, inflammatory, neuropathic and cancer pain models with behavioral pharmacology, post-operative pain models, CFA-induced models and clinically relevant readouts.
Itch
In Vivo Itch Models for Drug Development
Acute & Chronic Itch Models | Quantitative Assessment of Itch Behaviors | Video-Based Behavioral Analysis | Frequency & Duration-Based Scoring | Histological Analysis of Chronic Itch | Clinically relevant readouts
Inflammation & Immunology
LPS-Induced Inflammation & Cytokine Release Models | LPS-Induced Acute Lung Injury Model | DSS-Colitis Model of Inflammatory Bowel Disease | Dermal Inflammation Models (Imiquimod-Induced Psoriasis, Oxazolone-Induced DTH [Acute & Chronic], IL-23-Induced Inflammation) | Collagen-Induced Rheumatoid Arthritis | MOG35-55-Induced Experimental Autoimmune Encephalomyelitis (EAE) / Multiple Sclerosis
Supporting Analytical Services
Histology & Digital Pathology Services
Tissue processing, H&E, specialized staining, immunohistochemistry | Whole slide imaging | AI-driven quantitative analysis | High-throughput morphology assessment | Supporting all therapeutic areas.
Learn More
Discovery Biology & Assay Development
Target engagement assays | Biochemical and cell-based assays | Biomarker profiling | Receptor pharmacology | High-content imaging | Phenotypic screening.
Learn More
Adme/PK Services
In vivo PK studies | Radiolabeled ADME | Metabolite identification | Bioavailability assessment | Tissue distribution | PK/PD correlation.
Learn More
Glp Toxicology & Safety Studies
Single-dose toxicity | Repeat-dose studies | Safety pharmacology | Clinical pathology | Multi-species studies | Regulatory-ready documentation.
Learn More
Integrated Drug Discovery Programs & Scientific Consulting
End-to-end program management | DMTA cycle integration | Program strategy optimization | Scientific advisory services | Timeline-driven advancement.
Learn More
Client Testimonials
We are thoroughly impressed with your level of detail and communication efforts. We thank you and the Aragen team for getting us to this point in the study with confidence that you doing the very best to achieve a successful study.” “We have never had communication from a preclinical group at this level in our combined history of drug product development.
I’m working with the Aragen team now for more than twelve years. In every case and study, the team provides a high level of knowledge and service. Helping you to design the right study for you by performing extensive literature searches and exploring experimental possibilities to modify and accommodate models to your needs. Aragen distinguishes itself by service, speed, accuracy, and good communication with customers at a reasonable price.
